Schizophrenia Daily News Blog

Pfizer working on new Schizophrenia Drugs

At a research and development meeting for analysts on Nov. 30, Pfizer (PFE) talked about some Earlier-stage drugs - including offerings that could enhance the treatment of ailments including schizophrenia and asthma.

Asenapine is a novel treatment for schizophrenia.  Discovered by Organon Pharmaceuticals, it is being developed in a unique, under-the-tongue, fast-dissolving form.  Phase II trials showed promising efficacy against placebo and a comparator medicine.  Pfizer and its partner are developing asenapine for acute and maintenance treatment of schizophrenia and for the treatment of acute mania in bipolar disorder.

Varenicline is a medicine in development in pill form to reduce nicotine craving and diminish the rewards of smoking.  Feczko discussed a Phase II study confirming continuous quit rates of 51 percent.  Varenicline appears well-tolerated, and ongoing Phase III studies will further examine the medicine's ability to help smokers quit and remain smoke-free for the long term.